The FDA’s release of guidances for medical products communications and its publication of the intended use rule this month are nothing more than last-minute maneuvering, according to a former FDA official.
“These documents are being released late in the administration for a reason,” Coleen Klasmeier, a lawyer with Sidley Austin in Washington who was with the FDA’s Office of Chief Counsel, told me Jan. 18.
The documents in question are two draft guidances on manufacturer communications about medical products released Jan. 18 and a final rule on intended uses of drugs, devices and combination products published Jan. 9.
The first guidance contains recommendations to drug and device makers about how to communicate with payers, such as health insurers (Docket No. FDA-2016-D-1307). The second guidance explains how the FDA evaluates medical product communications, including promotional materials, that present information that isn’t in the FDA-approved labeling, but that refers to a product’s approved use (FDA-2016-D-2285). The agency also released a memorandum laying out issues it’s sorting through as it attempts to overhaul its policies on what manufacturers can say about the off-label uses of their products.
The new final intended use rule from the FDA clarifies for manufacturers when the agency will regulate tobacco products as drugs or devices and also contains amendments to regulations regarding intended uses.
"This area is fraught for FDA, and the timing indicates that agency—and especially HHS—officials are hoping to affect the incoming administration’s approach,” Klasmeier told me.
And, she said, the final intended use rule is “an eleventh-hour maneuver that was not the subject of proper notice in the 2015 proposed rule and further reflects the outgoing administration’s desire to tie the hands of the incoming team.”
The final rule intended use rule is at http://src.bna.com/lcM. The guidance on communications with payers is at http://src.bna.com/luG. The guidance on communication about approved uses is at http://src.bna.com/luK. The FDA's memorandum is at http://src.bna.com/lv5.
Read more about this in my story here.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)